

Market Scope[®]

2023 Retinal Pharmaceuticals Market Report

Global Analysis for 2022 to 2028

\$16.5B

2023 MARKET
FORECAST

318

COMPREHENSIVE
PAGES

29

COMPETITOR
PROFILES

8

GEOGRAPHIC AND
ECONOMIC BREAKOUTS

What's New

AUTHOR
Peter Downs

PUBLISHED
August 2023

The “2023 Retinal Pharmaceuticals Market Report” features new sales and disease prevalence forecasts through 2028. The report now covers adoption plans for complement inhibitors and new anti-VEGFs by ophthalmologists in the United States and Western Europe, as well as treatment patterns for anti-VEGFs. In addition, it includes IVT injection shares by drug in the United States and Western Europe.

The new report also evaluates more development-stage categories, therapies, and companies.

Market Scope


2023 Retinal Pharmaceuticals Market Report

The “2023 Retinal Pharmaceuticals Market Report” analyzes the market for the treatment of retinal diseases and discusses important trends and key factors for future market success. It examines the market’s evolution and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 29 competitors are profiled, with discussion of their products, strategic market position, background, and outlook. Our coverage includes:


- Discussions of retinal diseases and their risk factors.
- Diagnosis and treatment of these diseases.
- A global view of retinal care and retina specialists.
- Retinal pharmaceuticals and biologics in the marketplace.
- Investigational agents in the development pipeline.
- Profiles of companies developing and marketing retinal pharmaceuticals, plus a listing of additional companies with preclinical programs.

The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, biosimilars, complement inhibitors expected to enter the marketplace within five years, gene therapies, and others. The report also includes a separate forecast for sustained drug-delivery devices in retina and also delves into the development pipelines of 11 categories of retinal pharmaceuticals.

Retinal Pharmaceuticals Market Share in Revenue by Product



Global Prevalence of Retinal Diseases by Region in 2023



Market Scope designed this report to provide value to members of the ophthalmic industry who participate in the retinal pharmaceuticals market (or are weighing the option of doing so), market analysts, retina specialists, investors, and any other parties interested in the marketplace for these retinal treatments.

How to Order

Order your “2023 Retinal Pharmaceuticals Market Report” now at www.market-scope.com or contact us directly via email or phone.



ENTERPRISE LICENSE

2023 Retinal Pharmaceuticals
Market Report

\$12,750

(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)



SINGLE-USER LICENSE

2023 Retinal Pharmaceuticals
Market Report

\$8,500



Printed Copy

\$250



ONE-YEAR SUBSCRIPTION

Ophthalmic Market
Perspectives Newsletter

\$1,550



Monthly Paper Copies

\$100

314.835.0600 | info@market-scope.com

Our Process

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

